Clinical trials: Semaglutide
Overweight and Obesity
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
Novo Nordisk are doing this study to see if semaglutide tablets can be used as a treatment to help people living with overweight or obesity lose weight. This study will look at the change in participants' body weight.
- Trial name
- OASIS 2 (NCT05132088)
- Testing
- semaglutide 50 mg
- Where
- 15 sites in Japan, South Korea
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight.
- Trial name
- STEP HFpEF DM (NCT04916470)
- Testing
- Semaglutide
- Where
- 180 sites in United States, Argentina and 14 more
- Volunteers
- 617 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Impact of Semaglutide on CD34+ EPC and Fat Derived MSC
The Investigator is trying to ascertain whether an FDA approved medication of T2DM, Semaglutide, can improve the number, function and gene expression of subjects CD34+ endothelial progenitor cells.
- Trial name
- NCT04126603
- Testing
- Semaglutide
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Sabyasachi Sen
Diabetes Mellitus, Type 2
Treatment of GLP-1 for Diabetic Bariatric Patients
This study is for patients that are diabetic, and require insulin for glycemic control, and going through the bariatric surgery process.
- Trial name
- NOVO-GLP1 (NCT04624672)
- Testing
- Semaglutide (1 Mg Dose)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Geisinger Clinic
Diabetes, Diabetes Mellitus, Type 2
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment…
- Trial name
- NCT00696657
- Testing
- semaglutide, liraglutide
- Where
- 77 sites in Austria, Bulgaria and 12 more
- Volunteers
- 415 people
- Sponsor
- Novo Nordisk A/S
Metabolism and Nutrition Disorder, Overweight or Obesity
STEP 1: Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
This study will look at the change in participants' body weight from the start to the end of the study. The weight loss in participants taking semaglutide (a new medicine) will be compared to the weight loss of participants…
- Trial name
- STEP 1 (NCT03548935)
- Testing
- Semaglutide
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 1,961 people
- Sponsor
- Novo Nordisk A/S
Alzheimers Disease
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
The study is being conducted to understand how the medicine, semaglutide, affects the immune system and other biological processes in people with Alzheimer's disease.
- Trial name
- NCT05891496
- Testing
- Semaglutide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 23 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy"…
- Trial name
- NCT04102189
- Testing
- Semaglutide
- Where
- 51 sites in United States, Austria and 6 more
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Semaglutide in CFRD
This open label, single arm pilot study, will examine the safety and tolerability of GLP-1RA semaglutide as an add-on therapy to insulin for overweight/obese adult patients with cystic fibrosis related diabetes (CFRD).
- Trial name
- NCT05788965
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 2 (NCT02863328)
- Testing
- semaglutide, empagliflozin
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 822 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to examine the dose range, escalation and efficacy of oral semaglutide in subjects with type 2 diabetes.
- Trial name
- NCT01923181
- Testing
- semaglutide
- Where
- 103 sites in United States, Austria and 12 more
- Volunteers
- 632 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study to Investigate How Well NNC0165-1875 in Combination With Semaglutide Works in People With Obesity
The study is looking at a new medicine to help people lose weight. In this study participants will either get semaglutide and NNC0165-1875 or semaglutide and a "dummy" medicine (placebo).
- Trial name
- NCT04969939
- Testing
- Semaglutide 2.4 mg and NNC0165-1875 2.0 mg, Semaglutide 2.4 mg and NNC0165-1875 1.0 mg
- Where
- 25 sites in United States
- Volunteers
- 120 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only
This trial is conducted globally. The aim of this trial is to investigate efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only.
- Trial name
- PIONEER 1 (NCT02906930)
- Testing
- semaglutide
- Where
- 105 sites in United States, Algeria and 9 more
- Volunteers
- 703 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
A Phase 2b, study to measure the effect of Cotadutide at different doses versus placebo or comparator (semaglutide) in participants who have Chronic Kidney Disease with Type 2 Diabetes Mellitus.
- Trial name
- NCT04515849
- Testing
- Cotadutide 100 micrograms, Cotadutide 300 micrograms, Cotadutide 600 micrograms
- Where
- 83 sites in Australia, Canada and 6 more
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Overweight, Obesity
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 3 (NCT03611582)
- Testing
- Semaglutide
- Where
- 41 sites in United States
- Volunteers
- 611 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
This trial is conducted in Asia, Europe and North America. The aim of the trial is to compare the effect of semaglutide s.c. 1.0 mg once-weekly versus placebo as add-on to sodium glucose co-transporter-2 inhibitor (SGLT-2i)…
- Trial name
- SUSTAIN 9 (NCT03086330)
- Testing
- Semaglutide
- Where
- 72 sites in United States, Austria and 5 more
- Volunteers
- 302 people
- Sponsor
- Novo Nordisk A/S
Obesity
Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity
This study looks at how well semaglutide helps people lose weight. This study will look at the change in the participants' body weight from the start to the end of the study.
- Trial name
- NCT04998136
- Testing
- Semaglutide 2.4 mg
- Where
- 16 sites in South Korea, Thailand
- Volunteers
- 150 people
- Sponsor
- Novo Nordisk A/S
Tobacco Use Disorder, Nicotine Addiction
Effects of Semaglutide on Nicotine Intake
Tobacco use remains the foremost cause of preventable deaths in the U.S. and worldwide. Advancing new smoking cessation therapies, including those targeting novel biological mechanisms, is a critical public health priority.
- Trial name
- NCT05530577
- Testing
- Semaglutide
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill